14 hrs ago
Alexion Pharmaceuticals Inc. Sets New 1-Year High at $129.22
Alexion Pharmaceuticals set a new 52-week high during trading on Friday, ARN reports.
Sat Nov 30, 2013
Notable Movers- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Ocwen...
StockMarketIntel.com issues a special report on the following stocks: Alexion Pharmaceuticals, Inc. , Ocwen Financial Corp , Total SA , Republic Services, Inc. .
Tue Nov 26, 2013
Alexion Pharmaceuticals Receives New Coverage from Analysts at Piper Jaffray Cos.
The firm set an "overweight" rating on the stock. Alexion Pharmaceuticals traded down 0.22% on Tuesday, hitting $121.90.
Fri Nov 15, 2013
The Hartford Courant
Alexion: Recall Not Expected To Hurt Profit Forecast
Cheshire -based Alexion Pharmaceuticals announced this week that it is replacing some vials of Soliris because of visible particles floating in the medicine.
Tue Nov 12, 2013
Gilead Sciences Leads In Rising Short Interest Among Biotechs
Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals , BioMarin Pharmaceutical and Gilead Sciences grew by the largest percentages in late October.
Mon Nov 11, 2013
Alexion Pharmaceuticals Inc.'s Soliris (eculizumab) Inhibits...
SolirisA Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome CHESHIRE, CT, Nov. 9, 2013 /CNW/ - Alexion Pharmaceuticals, Inc. today announced that researchers presented data from four clinical trials, all demonstrating the clinical benefits of SolirisA for the treatment of atypical ... (more)
Sat Nov 09, 2013
Alexion Announces Data from Four Clinical Trials Demonstrate Clinical Benefits of Soliris
Alexion Pharmaceuticals today announced that researchers presented data from four clinical trials, all demonstrating the clinical benefits of SolirisA for the treatment of atypical hemolytic uremic syndrome , a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death.
Soliris (eculizumab) Inhibits TMA and Improves Renal Function in...
Soliris A Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome - New Data from the Largest Prospective Trial of Adult Patients with aHUS and First Prospective Trial in Pediatric Patients with aHUS Confirm the Safety and Efficacy Profile of Soliris -- - ASN Meeting Also Features Three-year ... (more)
Thu Nov 07, 2013
Investor's Business Daily
Alexion to Present at Credit Suisse 2013 Healthcare Conference
Alexion Pharmaceuticals, Inc. today announced that Vikas Sinha, Chief Financial Officer of Alexion Pharmaceuticals, will present at the Credit Suisse 2013 Healthcare Conference in Phoenix, Arizona at 9:30 a.m. Mountain Standard time on Thursday, November 14, 2013.
Researchers to Present Clinical Trial Data With SolirisA ...
Alexion Pharmaceuticals, Inc. today announced that researchers will present data from clinical studies of Soliris as a treatment for patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome , two life-threatening and ultra-rare diseases caused by chronic uncontrolled complement activation, at the 55th Annual Meeting ... (more)